



Myelomatosestudier

Fredrik Schjesvold, MD PhD
Head of Oslo Myeloma Center
Oslo University Hospital, Rikshospitalet

Studiepasienter / 100.000 i populasjon

Bærum	18,8
Kongsberg	15,0
Ringerike	13,8
OUS	12,4
Diakonhjemmet	9,5
Tønsberg	5,8
AHUS	5,2
Innlandet	4,7

Drammen	3,1
Telemark	2,9
Lovisenberg	2,5
Kristiansand	2,0
Østfold	1,8
Bodø	1,3
Haukeland	0,2

Studier som inkluderer nå - Førstelinje

Magnolia

- 2 år mot 4 år Zometa
- Kan inkluderes ved diagnose
(uansett alder)
- Kan inkluderes etter 2 år / 23-25 zometa
- Følges tett med CT og blodprøver

36 pasienter inkludert i Oslo

HOVON129

- Primær plasmacelleleukemi
- Carfilzomib + Revlimid + Dexa



(HMAS)



(Allo-tx)

1 pasient inkludert i Oslo

Studier som inkluderer nå - Tilbakefall

NMSG20/13

Første tilbakefall

- Carfilzomib-Sendoxan-Dexamethason
- HMAS
- Carfilzomib vs observasjon vedlikehold

46 pasienter inkludert i Oslo

ICARIA

Etter Revlimid og Velcade

- Pomalidomid/Imnovid + Dex til alle
- Isatuximab til 50%

5 pasienter inkludert i Oslo

Studier på gang på kort sikt

Førstelinje med HMAS

- Ixazomib-Revlimid-Dexamethason
- Januar?

Førstelinje konsolidering

- Carfilzomib-Revlimid-Dexamethason
- Januar?

Førstelinje høyrisk asymptomatisk MM

- Daratumumab vs observasjon
- Februar?

Tilbakefall etter revlimid og velcade

- 1) Melflufen vs Pomalidomid
 - November?
- 2) Cometinib vs C+Venetoclax vs C+V+Atezolizumab
 - November?
- 3) Ixazomib vs Pomalidomid
 - Januar?
- 4) APO010 i sensitive pasienter
 - Februar?

Oslo University Hospital

Divisions/Depts./Groups:

- + Cancer Medicine
 - Institute for Cancer Research
 - Institute for Cancer Genetics and Informatics
 - Dept. of Clinical Service
 - Dept. of Medical Physics
 - Dept. of Gyn. Oncology
 - Dept. of Oncology
 - Dept. of Haematology
 - Platelet and coagulation: clinical and basic research (Holme)
 - Oslo Myeloma Center (Schjesvold)**
 - Group members
 - About our research
 - Associated research groups
 - Trials
 - Publications
 - Scientists, Dept of Haematology
 - Publications, Dept of Haematology
 - Div. of Cancer Med Res Staff
 - Publications Cancer Clinic
- + Cardiovascular & Pulmonary Disease
- + Clinical Neuroscience
- + Emergencies and Critical Care
- + Gynaecology and Obstetrics
- + Head, Neck & Reconstr Surg
- + Laboratory Medicine
- + Medicine
- + Mental Health & Addiction
- + Orthopaedic surgery
- + Oslo Hospital Service (OSS)

Oslo Myeloma Center

Group leader: [Fredrik Schjesvold, MD](#)
Associated research doctors: [Nina Gulbrandsen, MD PhD](#), [Puneet Kaur](#), [Magnus Moksnes](#), [Anne Elisabeth Tonay Carlsen](#)
Research coordinator: [Anna Lysén](#)
Study nurses: [Ulla Madsen](#), [Marrydith Tran](#), [Kristin Låstad](#), [Larisa Myrseth](#), [Esther Morilla](#), [Hedda Nyhus](#), [Sylvia Rognli](#) og [Ann-Kristin Mitchell](#)
Study secretaries: [Ann Døli](#), [Liv Sigrun Eide](#), [Anita Husøy](#)



F. Schjesvold
Group leader

About our research:

Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics, with about 70-80 newly included patients a year. In 2016, nine studies have included patients, in young and elderly, in newly diagnosed and in patients with one or multiple relapses. We cooperate with basal and translational research groups, providing them with fresh cellular samples. In addition, we are creating a myeloma registry with a new database created by Medinsight



Trials

Ongoing trials:

- NMSG#20/13 - Carfilzomib-based ASCT for relapsed myeloma
- Magnolia - Zoledronic acid 2 years vs 4 years
- Panorama 3: Panobinostat-Velcade-Dexamethason randomized to different doses in relapse treatment
- HOVON129 - Treatment of primary plasma cell leukemia
- CA209-602: Elotuzumab, Nivolumab og Pomalidomid for >2 previous treatments
- IsatuximabPomDex vs PomDex 3.linje og utover
- Melflufen mot Pomalidomid 3 linje og utover

Upcoming trials:

- Ixazomib-Revlimid-Dexamethason in first line for the young
- Carfilzomib-Revlimid-Dexamethason as consolidation after first line therapy
- Daratumumab in smouldering myeloma
- Ixazomib vs Pomalidomide in relapsed myeloma
- Melflufen vs Pomalidomide in relapsed myeloma
- APO010 in drug sensitive relapsed myeloma
- Cometinib +/- venetoclax +/- atezolizumab in relapsed myeloma



Oslo myelomatosesenter

Spørsmål?

fredrikschjesvold@gmail.com